Natco Pharma reported a massive 57% year-on-year drop in net profit for the June quarter, primarily driven by declining sales of its key cancer drug, Lenalidomide.
Key Takeaways
- Net profit fell by 57% YoY to ₹206.5 crore.
- Total revenue saw a 43% decline due to lower Lenalidomide sales.
- Company shares tumbled over 5% following the announcement.
- An interim dividend of ₹1.5 per share has been declared.
Generic drugmaker Natco Pharma has reported a significant downturn in its financial performance for the June quarter. The company's consolidated net profit plummeted by 57% year-on-year, settling at ₹206.5 crore. This sharp decline has sent ripples through the stock market, with shares closing 5.23% lower at ₹902.40 on the BSE.
The slump in profitability is closely linked to a 43% dip in total revenue, which fell to ₹794.4 crore. According to the company, the primary driver behind this decline is the reduced sales of Lenalidomide, a generic version of the blockbuster cancer drug Revlimid. While the core business segments showed some growth, they were insufficient to offset the massive revenue loss from the oncology portfolio.
Why This Matters
BozokMedia analysis shows that Natco Pharma's heavy reliance on high-value specialty drugs like Lenalidomide makes its earnings highly sensitive to market fluctuations in the oncology segment. Any shift in generic competition or pricing dynamics in the US or international markets can lead to significant volatility in the company's bottom line.
Market analysts suggest that while the drop is steep, the company's strategic acquisition of stakes in Adcock Ingram could provide long-term stability.
Looking at the segmental breakdown, international formulations saw a sharp decline to ₹477.1 crore from ₹1,120.9 crore in the previous year. On a positive note, revenues from Active Pharmaceutical Ingredients (API) rose to ₹66.7 crore, and domestic pharmaceutical formulations also saw an uptick. Furthermore, Natco has increased its stake in the South African firm Adcock Ingram Holdings to 49%.
Historical Background
Natco Pharma has established itself as a significant player in the complex generic space. Historically, the company has relied on high-margin, specialized drugs to drive growth, a strategy that has yielded high rewards but also exposed them to concentration risks during periods of sales volatility.
Frequently Asked Questions
1. What caused the sudden drop in Natco Pharma's revenue?
The decline is largely attributed to lower sales earnings from the generic cancer drug Lenalidomide.
2. Has Natco Pharma declared any dividend?
Yes, the Board has declared an interim dividend of ₹1.5 per equity share.
